FDA
-
-
-
-
-
-
-
Altamira Therapeutics (CYTO) Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment
-
-
-
-
-
-
-
Altamira Therapeutics Provides Business Update and First Half 2023 Financial Results
-
-
-
-
-
-
-
Altamira Therapeutics (CYTO) Reports Publication of Positive Results from Phase 2 Trial with AM-125
-
-
-
-
-
-
-
Altamira Therapeutics (CYTO) Issues Year-End 2022 Business Update
-
-
-
-
-
-
-
Altamira Therapeutics (CYTO) Announces Data Published in Peer-Reviewed Journal Demonstrate Protective Effects of Bentrio under Controlled Grass Pollen Exposure
-
-
-
-
-
-
-
Altamira Therapeutics Re-launches Bentrio in Europe for Allergic Rhinitis
-
-
-
-
-
-
-
Altamira Therapeutics (CYTO) Secures Marketing & Distribution Agreements To Expand Sales Channels of Bentrio into Egypt and Pakistan
-
322,904 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

